NO312295B1 - Arylalkanoylpyridaziner, fremgangsmåte for fremstilling derav, farmasöytiske preparater, fremgangsmåte for fremstillingderav, samt anvendelse av forbindelsene til fremstilling avpreparatene - Google Patents

Arylalkanoylpyridaziner, fremgangsmåte for fremstilling derav, farmasöytiske preparater, fremgangsmåte for fremstillingderav, samt anvendelse av forbindelsene til fremstilling avpreparatene Download PDF

Info

Publication number: NO312295B1
Authority: NO; Norway
Prior art keywords: formula; compounds; tetrahydropyridazine; compound; preparation
Prior art date: 1996-08-13

Application number

NO19990676A

Other languages

English (en)

Norwegian (no)

Other versions

NO990676L (no

NO990676D0 (no

Inventor

Jonas Rochus

Norbert Beier

Franz-Werner Kluxen

Michael Wolf

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-13

Filing date

1999-02-12

Publication date

2002-04-22

1999-02-12 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

1999-02-12 Publication of NO990676L publication Critical patent/NO990676L/no

1999-02-12 Publication of NO990676D0 publication Critical patent/NO990676D0/no

2002-04-22 Publication of NO312295B1 publication Critical patent/NO312295B1/no

Links

150000001875 compounds Chemical class 0.000 title claims description 67
238000002360 preparation method Methods 0.000 title claims description 9
238000000034 method Methods 0.000 title claims description 8
239000000825 pharmaceutical preparation Substances 0.000 title claims description 6
239000000203 mixture Substances 0.000 title description 4
150000003839 salts Chemical class 0.000 claims description 21
238000006243 chemical reaction Methods 0.000 claims description 13
239000002253 acid Substances 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 7
239000000126 substance Substances 0.000 claims description 7
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
125000003545 alkoxy group Chemical group 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
208000006673 asthma Diseases 0.000 claims description 3
208000023275 Autoimmune disease Diseases 0.000 claims description 2
206010020751 Hypersensitivity Diseases 0.000 claims description 2
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 2
206010052779 Transplant rejections Diseases 0.000 claims description 2
230000007815 allergy Effects 0.000 claims description 2
150000007514 bases Chemical class 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims description 2
JBOOVPMFKCFZJB-UHFFFAOYSA-N ethyl n-[4-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCC)=CC=C1C(=O)N1N=C(C=2C=C(OC)C(OC)=CC=2)CCC1 JBOOVPMFKCFZJB-UHFFFAOYSA-N 0.000 claims description 2
AKPJSFRKAAXLDC-UHFFFAOYSA-N ethyl n-[4-[6-(3-cyclopentyloxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCC)=CC=C1C(=O)N1N=C(C=2C=C(OC3CCCC3)C(OC)=CC=2)CCC1 AKPJSFRKAAXLDC-UHFFFAOYSA-N 0.000 claims description 2
XZIQAKIJYXEIAQ-UHFFFAOYSA-N ethyl n-[4-[6-(3-ethoxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCC)=CC=C1C(=O)N1N=C(C=2C=C(OCC)C(OC)=CC=2)CCC1 XZIQAKIJYXEIAQ-UHFFFAOYSA-N 0.000 claims description 2
208000027866 inflammatory disease Diseases 0.000 claims description 2
239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 2
125000003373 pyrazinyl group Chemical group 0.000 claims description 2
125000004076 pyridyl group Chemical group 0.000 claims description 2
125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
239000007787 solid Substances 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
229940126601 medicinal product Drugs 0.000 claims 2
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 1
125000000753 cycloalkyl group Chemical group 0.000 claims 1
RLSSHCRYYPLVOB-UHFFFAOYSA-N n-[4-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]pyridine-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=CC(NC(=O)C=3C=NC=CC=3)=CC=2)CCC1 RLSSHCRYYPLVOB-UHFFFAOYSA-N 0.000 claims 1
LSKKFDJFMGJGGK-UHFFFAOYSA-N n-[4-[6-(3-cyclopentyloxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]pyridine-3-carboxamide Chemical compound COC1=CC=C(C=2CCCN(N=2)C(=O)C=2C=CC(NC(=O)C=3C=NC=CC=3)=CC=2)C=C1OC1CCCC1 LSKKFDJFMGJGGK-UHFFFAOYSA-N 0.000 claims 1
BILXGQUUIYPMDS-UHFFFAOYSA-N n-[4-[6-(3-cyclopentyloxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]pyridine-4-carboxamide Chemical compound COC1=CC=C(C=2CCCN(N=2)C(=O)C=2C=CC(NC(=O)C=3C=CN=CC=3)=CC=2)C=C1OC1CCCC1 BILXGQUUIYPMDS-UHFFFAOYSA-N 0.000 claims 1
RIQZGPJQTKTCNV-UHFFFAOYSA-N n-[4-[6-(3-ethoxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]pyridine-3-carboxamide Chemical compound C1=C(OC)C(OCC)=CC(C=2CCCN(N=2)C(=O)C=2C=CC(NC(=O)C=3C=NC=CC=3)=CC=2)=C1 RIQZGPJQTKTCNV-UHFFFAOYSA-N 0.000 claims 1
DOOCRWNRVGSKGN-UHFFFAOYSA-N n-[4-[6-(3-ethoxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]pyridine-4-carboxamide Chemical compound C1=C(OC)C(OCC)=CC(C=2CCCN(N=2)C(=O)C=2C=CC(NC(=O)C=3C=CN=CC=3)=CC=2)=C1 DOOCRWNRVGSKGN-UHFFFAOYSA-N 0.000 claims 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
-1 methoxy, ethoxy, propoxy Chemical group 0.000 description 16
239000000243 solution Substances 0.000 description 11
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
238000000354 decomposition reaction Methods 0.000 description 8
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
150000001412 amines Chemical class 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
239000003814 drug Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
239000007858 starting material Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000012154 double-distilled water Substances 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
239000012442 inert solvent Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
YWXBTQYFJSXXIN-UHFFFAOYSA-N (3-aminophenyl)-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(N)C=CC=2)CCC1 YWXBTQYFJSXXIN-UHFFFAOYSA-N 0.000 description 2
LIIAHUBAEAMYIF-UHFFFAOYSA-N (4-aminophenyl)-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=CC(N)=CC=2)CCC1 LIIAHUBAEAMYIF-UHFFFAOYSA-N 0.000 description 2
OTWPKCFAMVFCEG-UHFFFAOYSA-N (4-aminophenyl)-[6-(3-cyclopentyloxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]methanone Chemical compound COC1=CC=C(C=2CCCN(N=2)C(=O)C=2C=CC(N)=CC=2)C=C1OC1CCCC1 OTWPKCFAMVFCEG-UHFFFAOYSA-N 0.000 description 2
KFVCLUHRNKMMML-UHFFFAOYSA-N 2-(4-aminophenyl)-1-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]ethanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)CC=2C=CC(N)=CC=2)CCC1 KFVCLUHRNKMMML-UHFFFAOYSA-N 0.000 description 2
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
102000018594 Tumour necrosis factor Human genes 0.000 description 2
108050007852 Tumour necrosis factor Proteins 0.000 description 2
102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
235000011054 acetic acid Nutrition 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
MKZRYHJQHATKLV-UHFFFAOYSA-N diazinan-1-yl(phenyl)methanone Chemical compound C=1C=CC=CC=1C(=O)N1CCCCN1 MKZRYHJQHATKLV-UHFFFAOYSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000008298 dragée Substances 0.000 description 2
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
239000011521 glass Substances 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
KYYYPZBCJYAEMM-UHFFFAOYSA-N n-[4-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=CC(NC(=O)C=3C=NC=CC=3)=CC=2)CCC1 KYYYPZBCJYAEMM-UHFFFAOYSA-N 0.000 description 2
LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
235000011007 phosphoric acid Nutrition 0.000 description 2
239000006187 pill Substances 0.000 description 2
WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 2
RVQZKNOMKUSGCI-UHFFFAOYSA-N pyridine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC=C1 RVQZKNOMKUSGCI-UHFFFAOYSA-N 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
UGRNVLGKAGREKS-GCXDCGAKSA-N (1r,2s,3r,5r)-3-(6-aminopurin-9-yl)-5-(hydroxymethyl)cyclopentane-1,2-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1C[C@H](CO)[C@@H](O)[C@H]1O UGRNVLGKAGREKS-GCXDCGAKSA-N 0.000 description 1
PSOOLGWZIDQSCW-UHFFFAOYSA-N (2-aminophenyl)-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=CC=CC=2)N)CCC1 PSOOLGWZIDQSCW-UHFFFAOYSA-N 0.000 description 1
MMMSCVHAJVYWJL-UHFFFAOYSA-N (3-aminophenyl)-[6-(3-cyclopentyloxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]methanone Chemical compound COC1=CC=C(C=2CCCN(N=2)C(=O)C=2C=C(N)C=CC=2)C=C1OC1CCCC1 MMMSCVHAJVYWJL-UHFFFAOYSA-N 0.000 description 1
PLSBERZNVIRBKE-UHFFFAOYSA-N (4-aminophenyl)-[6-(3-ethoxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]methanone Chemical compound C1=C(OC)C(OCC)=CC(C=2CCCN(N=2)C(=O)C=2C=CC(N)=CC=2)=C1 PLSBERZNVIRBKE-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
BGMLUCPALPKNOV-UHFFFAOYSA-N 1,4,5,6-tetrahydropyridazine Chemical compound C1CNN=CC1 BGMLUCPALPKNOV-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
PAUYHIAYDSDBIU-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-1,4,5,6-tetrahydropyridazine Chemical compound C1=C(OC)C(OC)=CC=C1C1=NNCCC1 PAUYHIAYDSDBIU-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
QHGNTSHHMRPPTI-UHFFFAOYSA-N 4-(pyridine-3-carbonylamino)benzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1NC(=O)C1=CC=CN=C1 QHGNTSHHMRPPTI-UHFFFAOYSA-N 0.000 description 1
OYYQGBCCGQJUIO-UHFFFAOYSA-N 4-(pyridine-4-carbonylamino)benzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1NC(=O)C1=CC=NC=C1 OYYQGBCCGQJUIO-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010021118 Hypotonia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
208000012658 Skin autoimmune disease Diseases 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
AOXNCGBBKGTMEE-UHFFFAOYSA-N [6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]-(4-nitrophenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=CC(=CC=2)[N+]([O-])=O)CCC1 AOXNCGBBKGTMEE-UHFFFAOYSA-N 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000002723 alicyclic group Chemical group 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
150000003938 benzyl alcohols Chemical class 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000000000 cycloalkoxy group Chemical group 0.000 description 1
125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
201000010099 disease Diseases 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
239000006196 drop Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
ZHPBSMNDJPBJSG-UHFFFAOYSA-N ethyl n-[3-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]carbamate Chemical compound CCOC(=O)NC1=CC=CC(C(=O)N2N=C(CCC2)C=2C=C(OC)C(OC)=CC=2)=C1 ZHPBSMNDJPBJSG-UHFFFAOYSA-N 0.000 description 1
NSGQBSCYMVJBTC-UHFFFAOYSA-N ethyl n-[4-[2-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]-2-oxoethyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCC)=CC=C1CC(=O)N1N=C(C=2C=C(OC)C(OC)=CC=2)CCC1 NSGQBSCYMVJBTC-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000012467 final product Substances 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
IBFVVGPHIPDSPN-UHFFFAOYSA-N methyl n-[4-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OC)=CC=C1C(=O)N1N=C(C=2C=C(OC)C(OC)=CC=2)CCC1 IBFVVGPHIPDSPN-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000036640 muscle relaxation Effects 0.000 description 1
LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
FMHABHMWHMUEHH-UHFFFAOYSA-N n-[3-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]pyrazine-2-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(NC(=O)C=3N=CC=NC=3)C=CC=2)CCC1 FMHABHMWHMUEHH-UHFFFAOYSA-N 0.000 description 1
DGHSMSUWDUKQSL-UHFFFAOYSA-N n-[3-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(NC(=O)C=3C=NC=CC=3)C=CC=2)CCC1 DGHSMSUWDUKQSL-UHFFFAOYSA-N 0.000 description 1
FQYIREXXTRFLEI-UHFFFAOYSA-N n-[3-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]pyridine-4-carboxamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(NC(=O)C=3C=CN=CC=3)C=CC=2)CCC1 FQYIREXXTRFLEI-UHFFFAOYSA-N 0.000 description 1
KDYLZVRQZQKLGQ-UHFFFAOYSA-N n-[3-[6-(3-ethoxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OCC)=CC(C=2CCCN(N=2)C(=O)C=2C=C(NC(=O)C=3C=NC=CC=3)C=CC=2)=C1 KDYLZVRQZQKLGQ-UHFFFAOYSA-N 0.000 description 1
DHQBKIXRUFVFCO-UHFFFAOYSA-N n-[4-[2-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]-2-oxoethyl]phenyl]pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)CC=2C=CC(NC(=O)C=3C=NC=CC=3)=CC=2)CCC1 DHQBKIXRUFVFCO-UHFFFAOYSA-N 0.000 description 1
AUEYPIWSHYIDLS-UHFFFAOYSA-N n-[4-[2-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazin-2-yl]-2-oxoethyl]phenyl]pyridine-4-carboxamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)CC=2C=CC(NC(=O)C=3C=CN=CC=3)=CC=2)CCC1 AUEYPIWSHYIDLS-UHFFFAOYSA-N 0.000 description 1
IJJBJNLARIXCQR-UHFFFAOYSA-N n-[4-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=CC(NC(C)=O)=CC=2)CCC1 IJJBJNLARIXCQR-UHFFFAOYSA-N 0.000 description 1
JQADVWXRFVQNQJ-UHFFFAOYSA-N n-[4-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]pyrazine-2-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=CC(NC(=O)C=3N=CC=NC=3)=CC=2)CCC1 JQADVWXRFVQNQJ-UHFFFAOYSA-N 0.000 description 1
SKAJNAKRAXUINO-UHFFFAOYSA-N n-[4-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]pyridine-4-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=CC(NC(=O)C=3C=CN=CC=3)=CC=2)CCC1 SKAJNAKRAXUINO-UHFFFAOYSA-N 0.000 description 1
NACWCMNWYSUONT-UHFFFAOYSA-N n-[4-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]pyridine-4-carboxamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=CC(NC(=O)C=3C=CN=CC=3)=CC=2)CCC1 NACWCMNWYSUONT-UHFFFAOYSA-N 0.000 description 1
CCPCXYSMLOVMQV-UHFFFAOYSA-N n-[4-[6-(3,4-dimethoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]pyrimidine-4-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=CC(NC(=O)C=3N=CN=CC=3)=CC=2)CCC1 CCPCXYSMLOVMQV-UHFFFAOYSA-N 0.000 description 1
NOCFPFOHJDHTIO-UHFFFAOYSA-N n-[4-[6-(3-cyclopentyloxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]pyridine-3-carboxamide;hydrochloride Chemical compound Cl.COC1=CC=C(C=2CCCN(N=2)C(=O)C=2C=CC(NC(=O)C=3C=NC=CC=3)=CC=2)C=C1OC1CCCC1 NOCFPFOHJDHTIO-UHFFFAOYSA-N 0.000 description 1
XMBHVJDTTIQNPA-UHFFFAOYSA-N n-[4-[6-(3-cyclopentyloxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]pyridine-4-carboxamide;hydrochloride Chemical compound Cl.COC1=CC=C(C=2CCCN(N=2)C(=O)C=2C=CC(NC(=O)C=3C=CN=CC=3)=CC=2)C=C1OC1CCCC1 XMBHVJDTTIQNPA-UHFFFAOYSA-N 0.000 description 1
HMZSBEMBRTUMMZ-UHFFFAOYSA-N n-[4-[6-(3-ethoxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]pyrazine-2-carboxamide Chemical compound C1=C(OC)C(OCC)=CC(C=2CCCN(N=2)C(=O)C=2C=CC(NC(=O)C=3N=CC=NC=3)=CC=2)=C1 HMZSBEMBRTUMMZ-UHFFFAOYSA-N 0.000 description 1
LRQRETUKURIPOK-UHFFFAOYSA-N n-[4-[6-(3-ethoxy-4-methoxyphenyl)-4,5-dihydro-3h-pyridazine-2-carbonyl]phenyl]pyridine-4-carboxamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OCC)=CC(C=2CCCN(N=2)C(=O)C=2C=CC(NC(=O)C=3C=CN=CC=3)=CC=2)=C1 LRQRETUKURIPOK-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
150000002828 nitro derivatives Chemical class 0.000 description 1
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
102000003998 progesterone receptors Human genes 0.000 description 1
108090000468 progesterone receptors Proteins 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
238000000746 purification Methods 0.000 description 1
TXJKATOSKLUITR-UHFFFAOYSA-N pyrazine-2-carbonyl chloride Chemical compound ClC(=O)C1=CN=CC=N1 TXJKATOSKLUITR-UHFFFAOYSA-N 0.000 description 1
OMTUOKCYZDAJMI-UHFFFAOYSA-N pyrimidine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC=N1 OMTUOKCYZDAJMI-UHFFFAOYSA-N 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000000542 sulfonic acid group Chemical group 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
230000007306 turnover Effects 0.000 description 1
229940099259 vaseline Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)

NO19990676A 1996-08-13 1999-02-12 Arylalkanoylpyridaziner, fremgangsmåte for fremstilling derav, farmasöytiske preparater, fremgangsmåte for fremstillingderav, samt anvendelse av forbindelsene til fremstilling avpreparatene NO312295B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19632549A DE19632549A1 (de)	1996-08-13	1996-08-13	Arylalkanoylpyridazine
PCT/EP1997/004191 WO1998006704A1 (de)	1996-08-13	1997-08-01	Arylalkanoylpyridazine

Publications (3)

Publication Number	Publication Date
NO990676L NO990676L (no)	1999-02-12
NO990676D0 NO990676D0 (no)	1999-02-12
NO312295B1 true NO312295B1 (no)	2002-04-22

Family

ID=7802479

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19990676A NO312295B1 (no)	1996-08-13	1999-02-12	Arylalkanoylpyridaziner, fremgangsmåte for fremstilling derav, farmasöytiske preparater, fremgangsmåte for fremstillingderav, samt anvendelse av forbindelsene til fremstilling avpreparatene

Country Status (23)

Country	Link
US (1)	US6479494B1 (es)
EP (1)	EP0922036B1 (es)
KR (1)	KR100554876B1 (es)
CN (1)	CN1109022C (es)
AR (1)	AR009069A1 (es)
AT (1)	ATE262512T1 (es)
AU (1)	AU725652B2 (es)
BR (1)	BR9711066A (es)
CA (1)	CA2263417C (es)
CZ (1)	CZ291851B6 (es)
DE (2)	DE19632549A1 (es)
DK (1)	DK0922036T3 (es)
ES (1)	ES2214633T3 (es)
HU (1)	HUP0001760A3 (es)
NO (1)	NO312295B1 (es)
PL (1)	PL331557A1 (es)
PT (1)	PT922036E (es)
RU (1)	RU2201923C2 (es)
SI (1)	SI0922036T1 (es)
SK (1)	SK282480B6 (es)
TW (1)	TW427980B (es)
WO (1)	WO1998006704A1 (es)
ZA (1)	ZA977206B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19826841A1 (de) *	1998-06-16	1999-12-23	Merck Patent Gmbh	Arylalkanoylpyridazine
DE19850701A1 (de)	1998-11-04	2000-05-11	Merck Patent Gmbh	Benzoylpyridazine
DE19915365A1 (de) *	1999-04-06	2000-10-12	Merck Patent Gmbh	Tetrahydropyridazin-Derivate
DE19915364A1 (de) *	1999-04-06	2000-10-12	Merck Patent Gmbh	Verwendung von Arylalkanoylpyridazinen
DE19932315A1 (de)	1999-07-10	2001-01-11	Merck Patent Gmbh	Benzoylpyridazine
AU777012B2 (en)	1999-08-21	2004-09-30	Takeda Gmbh	Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist
US6794132B2 (en)	1999-10-02	2004-09-21	Biosite, Inc.	Human antibodies
US7135287B1 (en)	1999-10-02	2006-11-14	Biosite, Inc.	Human antibodies
US6680209B1 (en)	1999-12-06	2004-01-20	Biosite, Incorporated	Human antibodies as diagnostic reagents
DE10064997A1 (de)	2000-12-23	2002-06-27	Merck Patent Gmbh	Benzoylpyridazine
WO2002072103A1 (en) *	2001-02-12	2002-09-19	Merck Patent Gmbh	Use of type 4 phosphodiesterase inhibitors in myocardial diseases
CA2462525A1 (en) *	2001-10-31	2003-05-08	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Type 4 phosphodiesterase inhibitors and uses thereof
KR100898894B1 (ko) *	2001-11-05	2009-05-21	메르크 파텐트 게엠베하	히드라조노-말로니트릴
DE10224888A1 (de) *	2002-06-05	2003-12-24	Merck Patent Gmbh	Pyridazinderivate
DE10225574A1 (de) *	2002-06-10	2003-12-18	Merck Patent Gmbh	Aryloxime
DE10227269A1 (de) *	2002-06-19	2004-01-08	Merck Patent Gmbh	Thiazolderivate
JP2006522151A (ja)	2003-04-01	2006-09-28	アプライドリサーチシステムズエーアールエスホールディングナームロゼフェンノートシャップ	不妊症におけるホスホジエステラーゼ阻害剤
ES2270715B1 (es) *	2005-07-29	2008-04-01	Laboratorios Almirall S.A.	Nuevos derivados de pirazina.
EP1928437A2 (en)	2005-08-26	2008-06-11	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009512711A (ja)	2005-10-21	2009-03-26	ブレインセルス，インコーポレイティド	Ｐｄｅ阻害による神経新生の調節
WO2007053596A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
AR057891A1 (es)	2005-11-15	2007-12-26	Otsuka Pharma Co Ltd	Compuestos de oxazol y composicion farmaceutica
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2026813A2 (en)	2006-05-09	2009-02-25	Braincells, Inc.	5 ht receptor mediated neurogenesis
WO2007134136A2 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
WO2008030651A1 (en) *	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
EP2804603A1 (en)	2012-01-10	2014-11-26	President and Fellows of Harvard College	Beta-cell replication promoting compounds and methods of their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5175161A (en) *	1989-04-06	1992-12-29	Sankyo Company, Limited	Occular hypotensive agents
JO1645B1 (en) *	1989-12-26	1991-11-27	شركة جانسين فارماسوتيكا ان. في	Pyridazine compounds are antibacterial viruses
NZ254534A (en)	1992-07-01	1997-12-19	Ortho Pharma Corp	1,4,5,6-tetrahydro-pyridazine derivatives, preparation and pharmaceutical compositions thereof

1996
- 1996-08-13 DE DE19632549A patent/DE19632549A1/de not_active Withdrawn
1997
- 1997-08-01 PT PT97937540T patent/PT922036E/pt unknown
- 1997-08-01 CN CN97197181A patent/CN1109022C/zh not_active Expired - Fee Related
- 1997-08-01 RU RU99105211/04A patent/RU2201923C2/ru not_active IP Right Cessation
- 1997-08-01 HU HU0001760A patent/HUP0001760A3/hu unknown
- 1997-08-01 CZ CZ1999493A patent/CZ291851B6/cs not_active IP Right Cessation
- 1997-08-01 DK DK97937540T patent/DK0922036T3/da active
- 1997-08-01 KR KR1019997001132A patent/KR100554876B1/ko not_active Expired - Fee Related
- 1997-08-01 AT AT97937540T patent/ATE262512T1/de not_active IP Right Cessation
- 1997-08-01 CA CA002263417A patent/CA2263417C/en not_active Expired - Fee Related
- 1997-08-01 BR BR9711066A patent/BR9711066A/pt not_active IP Right Cessation
- 1997-08-01 WO PCT/EP1997/004191 patent/WO1998006704A1/de not_active Ceased
- 1997-08-01 SI SI9730631T patent/SI0922036T1/xx unknown
- 1997-08-01 SK SK168-99A patent/SK282480B6/sk not_active IP Right Cessation
- 1997-08-01 ES ES97937540T patent/ES2214633T3/es not_active Expired - Lifetime
- 1997-08-01 DE DE59711450T patent/DE59711450D1/de not_active Expired - Lifetime
- 1997-08-01 EP EP97937540A patent/EP0922036B1/de not_active Expired - Lifetime
- 1997-08-01 AU AU40133/97A patent/AU725652B2/en not_active Ceased
- 1997-08-01 PL PL97331557A patent/PL331557A1/xx unknown
- 1997-08-11 TW TW086111479A patent/TW427980B/zh active
- 1997-08-12 ZA ZA9707206A patent/ZA977206B/xx unknown
- 1997-08-13 AR ARP970103679A patent/AR009069A1/es not_active Application Discontinuation
1999
- 1999-02-12 NO NO19990676A patent/NO312295B1/no not_active IP Right Cessation
2000
- 2000-03-15 US US09/525,455 patent/US6479494B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
SI0922036T1 (en)	2004-06-30
ZA977206B (en)	1999-11-12
CZ291851B6 (cs)	2003-06-18
ATE262512T1 (de)	2004-04-15
SK16899A3 (en)	1999-12-10
BR9711066A (pt)	1999-08-17
EP0922036B1 (de)	2004-03-24
DE59711450D1 (en)	2004-04-29
RU2201923C2 (ru)	2003-04-10
AU4013397A (en)	1998-03-06
KR20000029921A (ko)	2000-05-25
NO990676L (no)	1999-02-12
CN1109022C (zh)	2003-05-21
CN1227547A (zh)	1999-09-01
JP2001503022A (ja)	2001-03-06
JP4198755B2 (ja)	2008-12-17
AU725652B2 (en)	2000-10-19
HK1021732A1 (en)	2000-06-30
SK282480B6 (sk)	2002-02-05
TW427980B (en)	2001-04-01
NO990676D0 (no)	1999-02-12
HUP0001760A2 (hu)	2001-05-28
CZ49399A3 (cs)	1999-05-12
HUP0001760A3 (en)	2001-07-30
WO1998006704A1 (de)	1998-02-19
CA2263417C (en)	2006-03-28
EP0922036A1 (de)	1999-06-16
DE19632549A1 (de)	1998-02-19
KR100554876B1 (ko)	2006-02-24
ES2214633T3 (es)	2004-09-16
PL331557A1 (en)	1999-07-19
CA2263417A1 (en)	1998-02-19
DK0922036T3 (da)	2004-07-26
AR009069A1 (es)	2000-03-08
PT922036E (pt)	2004-06-30
US6479494B1 (en)	2002-11-12

Publication	Publication Date	Title
NO312295B1 (no)	2002-04-22	Arylalkanoylpyridaziner, fremgangsmåte for fremstilling derav, farmasöytiske preparater, fremgangsmåte for fremstillingderav, samt anvendelse av forbindelsene til fremstilling avpreparatene
NO309679B1 (no)	2001-03-12	Arylalkyldiazinoner, farmasöytiske preparater og anvendelse av forbindelsene til fremstilling av legemidler
AU750019B2 (en)	2002-07-11	Aryl alkanoylpyridazines
NO329935B1 (no)	2011-01-24	Kinolinderivater og deres anvendelse som mykobakterielle inhibitorer
CN105814050A (zh)	2016-07-27	用作tnf活性调节剂的吡唑并吡啶衍生物
CN105814041A (zh)	2016-07-27	用作tnf活性调节剂的苯并三唑衍生物
PL217872B1 (pl)	2014-08-29	Pochodna eteru alkilowego lub jej sól, stanowiąca 1-{3-[2-(1-benzotiofen-5-ylo)etoksy]propylo}-3-azetydynol lub jego sól
IL296413A (en)	2022-11-01	gpr52 modulator compounds
EP0769007A1 (en)	1997-04-23	2-ureido-benzamide derivatives
KR20190005877A (ko)	2019-01-16	Trpv4 길항제
AU759328B2 (en)	2003-04-10	Benzoylpyridazines
AU2004228121A1 (en)	2004-10-21	1,3,4-substituted pyrazoles for use as 5-HT receptor antagonists in the treatment of psychoses and neurological disorders
WO2001032173A1 (en)	2001-05-10	Kainic acid neurocytotoxicity inhibitors
DE19707628A1 (de)	1998-08-27	Oxazolidinone
US6107295A (en)	2000-08-22	Arylalkanoyl pyridazines
MX2011004903A (es)	2011-05-30	Pirrolidinas.
NO323263B1 (no)	2007-02-19	Heterosyklisk derivat, fremgangsmater for dets fremstilling, farmasoytiske sammensetninger som inneholder dette, anvendelse av dette for fremstilling av et preparat for medisinsk bruk samt nevnte derivat til bruk som medikament
MXPA01010034A (es)	2002-04-24	Uso de arilalcanoilpiridazinas.
JP4198755B6 (ja)	2009-04-15	アリールアルカノイルピリダジン誘導体
Branigan	1995	Darmstadt, all of Germany
HK1039329B (en)	2004-04-16	Pyrazolecarboxylic acid derivatives, their preparation, pharmaceutical compositions containing them
HK1039329A1 (en)	2002-04-19	Pyrazolecarboxylic acid derivatives, their preparation, pharmaceutical compositions containing them
MXPA99001386A (es)	1999-09-20	Arilalcanoilpiridazinas
MXPA00012592A (es)	2001-09-07	Arilalcanoilpiridazinas
JPWO2001032173A1 (ja)	2003-05-20	カイニン酸神経細胞毒性阻害剤

Legal Events

Date	Code	Title	Description
2011-04-04	MM1K	Lapsed by not paying the annual fees